Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2771244 | Seminars in Anesthesia, Perioperative Medicine and Pain | 2006 | 7 Pages |
Abstract
Dexmedetomidine (DMET) is an alpha-2 adrenoceptor agonist approved for short-term use as a sedative for mechanically ventilated patients. Alpha-2 adrenoceptor agonists exhibit sedative–hypnotic, analgesic, anxiolytic, and sympatholytic effects. The ability of DMET to produce a readily arousable state of moderate–deep sedation and analgesia with a lack of respiratory depression has led to an increased interest in its use. Very little published data exists on the side effects/adverse event profile of the drug, especially with high-dose prolonged infusions. In addition, the ceiling dose is not really known. This article reviews the current literature with regards to multiple organ systems and the effects of DMET.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Deborah S. Wagner, Chad M. Brummett,